HK Stock Market Move | LAEKNA-B(02105) surged more than 5% in early trading. LAE002 is expected to submit NDA in the first half of 2026.

LAEKNA-B(02105) rose over 5% in early trading, up 5.63% as of the time of writing, at 16.9 Hong Kong dollars, with a trading volume of 28.6972 million Hong Kong dollars. On the news front, Laikena Pharmaceuticals previously signed an exclusive agreement with Qilu Pharmaceuticals to license Qilu Pharmaceuticals to research, develop and commercialize LAE002 in China. The company is responsible for completing the Phase III clinical trial of HR+/HER2- breast cancer, until the first indication is approved for a new drug application in China, with the right to receive a non-refundable upfront payment and clinical development milestone payments of up to 530 million RMB, and potentially up to 2.045 billion RMB, along with a sales share of over ten to twenty percentage points of net sales in the licensed area. Yongxing Securities released a research report stating that LAE002 is expected to submit an NDA in the first half of 2026. The company's pipeline is progressing smoothly, with LAE002 licensed to Qilu, excellent MAD data for LAE102, and FDA approval for the IND application of LAE103; the firm uses the DCF valuation method for LAE102, initiates coverage with a "buy" rating for the company.